References

The World Health Organization (WHO) approach to healthy ageing

10.1016/j.maturitas.2020.05.018 · 2020 · External reference

Global prevalence of pancreatic cystic lesions in the general population on magnetic resonance imaging: a systematic review and meta-analysis

10.1016/j.cgh.2024.02.018 · 2024 · External reference

American Gastroenterological Association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts

10.1053/j.gastro.2015.01.014 · 2015 · External reference

Long-term risk of malignancy in branch-duct intraductal papillary mucinous neoplasms

10.1053/j.gastro.2019.08.032 · 2020 · External reference

Real-World trends and future projections of the prevalence of cirrhosis and hepatic encephalopathy among commercially and medicare-insured adults in the United States

10.14309/ctg.0000000000000823 · 2025 · External reference

Estimated burden of metabolic dysfunction–associated steatotic liver disease in US adults, 2020 to 2050

10.1001/jamanetworkopen.2024.54707 · 2025 · External reference

AGA clinical practice update on surveillance of metaplastic and premalignant conditions of the esophagus and colorectum in older adults: expert review

10.1016/j.cgh.2026.06.007 · 2026 · External reference

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

10.1097/hep.0000000000000466 · 2023 · External reference

What is the incidence of malignancy in resected intraductal papillary mucinous neoplasms? An analysis of over 100 US institutions in a single year

10.1245/s10434-018-6425-6 · 2018 · External reference

Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma

10.1002/jso.24125 · 2016 · External reference

Mapping global new-onset, worsening, and resolution of diabetes following partial pancreatectomy: a systematic review and meta-analysis

10.1097/js9.0000000000000998 · 2024 · External reference

Surveillance for presumed BD-IPMN of the pancreas: stability, size, and Age identify targets for discontinuation

10.1053/j.gastro.2023.06.022 · 2023 · External reference

The surveillance strategy for intraductal pancreatic mucinous neoplasms: criteria for discontinuation

10.1097/sla.0000000000006580 · 2026 · External reference

New surgical criteria for intraductal papillary mucinous neoplasm based on the age-adjusted charlson comorbidity index values and presence of solid component

2024 · External reference

Distinct prognostic impacts of age-adjusted Charlson comorbidity index and geriatric nutritional risk index in patients with intraductal papillary mucinous neoplasm

10.1097/md.0000000000041215 · 2025 · External reference

Competing risks for mortality in patients with asymptomatic pancreatic cystic neoplasms: implications for clinical management

10.1038/ajg.2017.141 · 2017 · External reference

Effects of comorbidities on outcomes of patients with intraductal papillary mucinous neoplasms

2015 · External reference

American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts

10.1053/j.gastro.2015.01.015 · 2015 · External reference

Long-term risk of pancreatic malignancy in patients with branch duct intraductal papillary mucinous neoplasm in a referral Center

10.1053/j.gastro.2017.07.019 · 2017 · External reference

Progression of pancreatic branch duct intraductal papillary mucinous Neoplasm Associates with cyst size

10.1053/j.gastro.2017.10.013 · 2018 · External reference

Long-Term outcomes and risk of pancreatic cancer in intraductal papillary mucinous neoplasms

10.1001/jamanetworkopen.2023.37799 · 2023 · External reference

Identification of patients with branch-duct intraductal papillary mucinous neoplasm and very low risk of cancer: Multicentre study

10.1093/bjs/znac103 · 2022 · External reference

The faith of non-surveilled pancreatic cysts: a bicentric retrospective study

10.1016/j.ejso.2021.06.007 · 2022 · External reference

IPMNs with co-occurring invasive cancers: neighbours but not always relatives

10.1136/gutjnl-2017-315062 · 2018 · External reference

Intraductal papillary mucinous neoplasm surveillance leads to early diagnosis and better outcomes of concomitant cancer

10.1097/sla.0000000000006268 · 2025 · External reference

The surveillance strategy for intraductal pancreatic mucinous neoplasms: criteria for discontinuation

2024 · External reference

International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas

2024 · External reference

ACG clinical guideline: diagnosis and management of pancreatic cysts

10.1038/ajg.2018.14 · 2018 · External reference

European evidence-based guidelines on pancreatic cystic neoplasms

10.1136/gutjnl-2018-316027 · 2018 · External reference

Surveillance after resection of non-invasive intraductal papillary mucinous neoplasms (IPMN). A systematic review

2023 · External reference

Invasive and noninvasive progression after resection of noninvasive intraductal papillary mucinous neoplasms

10.1097/sla.0000000000004488 · 2022 · External reference

Efficacy and tolerability of direct-acting antivirals for hepatitis C in older adults

10.1111/jgs.15392 · 2018 · External reference

AASLD IDSA Practice Guideline on treatment of chronic hepatitis B

10.1097/hep.0000000000001549 · 2026 · External reference

HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma

2017 · External reference

Association of direct-acting antiviral therapy with liver and nonliver complications and long-term mortality in patients with chronic hepatitis C

10.1001/jamainternmed.2022.5699 · 2023 · External reference

Assessing the impact of direct-acting antivirals on hepatitis C complications: a systematic review and meta-analysis

10.1007/s00210-023-02716-x · 2024 · External reference

Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus

10.1371/journal.pone.0262267 · 2022 · External reference

A novel scoring system to identify patients at low risk for hepatocellular carcinoma five years after DAA-Induced sustained virological response: a retrospective cohort study

10.1186/s12876-025-04451-4 · 2025 · External reference

KDIGO 2022 Clinical Practice Guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease

10.1016/j.kint.2022.07.013 · 2022 · External reference

Mechanisms and clinical significance of pharmacokinetic drug interactions mediated by FDA and EMA-approved hepatitis C direct-acting antiviral agents

10.1007/s40262-023-01302-x · 2023 · External reference

Considerations in the diagnoses and management of hepatic disease in older adults

10.14309/ajg.0000000000003641.07 · 2025 · External reference

Undiagnosed cirrhosis occurs frequently in the elderly and requires periodic follow ups and medical treatments

10.1111/j.1447-0594.2008.00470.x · 2008 · External reference

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

10.1097/hep.0000000000000466 · 2023 · External reference

Clinical characteristics associated with posttransplant survival among adults 70 years old or older undergoing liver transplantation

10.1097/mcg.0000000000001870 · 2024 · External reference

Safety and effectiveness of transarterial chemoembolization in hepatocellular carcinoma patients aged greater versus less than 80 years

10.2147/cia.s429259 · 2023 · External reference

Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality

10.1053/j.gastro.2017.02.040 · 2017 · External reference

The genomic and epigenomic abnormalities of plasma cfDNA as liquid biopsy biomarkers to detect hepatocellular carcinoma: a multicenter cohort study

10.1186/s13045-025-01747-6 · 2025 · External reference